Non-Small Cell Lung Cancer New Indication: Osimertinib after Chemoradiotherapy in NSCLC Ulas D. Bayraktar, MD 2024-09-30
Non-Small Cell Lung Cancer New Drug: Lazertinib for EGFR mutated NSCLC Ulas D. Bayraktar, MD 2024-08-27
Non-Small Cell Lung Cancer New Drug: Repotrectinib for ROS1-fusion positive NSCLC Ulas D. Bayraktar, MD 2024-06-21
Non-Small Cell Lung Cancer New Indication: Perioperative Durvalumab for NSCLC Ulas D. Bayraktar, MD 2023-11-20
Non-Small Cell Lung Cancer New Indication: Osimertinib in First-Line NSCLC Ulas D. Bayraktar, MD 2023-11-20
Non-Small Cell Lung Cancer New Indication: Trastuzumab Deruxtecan for her2 Mutant NSCLC Ulas D. Bayraktar, MD 2023-09-23
Non-Small Cell Lung Cancer New Indication: Pembrolizumab for Early-Stage NSCLC Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Indication: Perioperative Nivolumab and Chemotherapy for Stage III NSCLC Ulas D. Bayraktar, MD 2023-08-20
Non-Small Cell Lung Cancer New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC Ulas D. Bayraktar, MD 2023-06-24
